Jun 14, 2025
Bevixa 400 mg Injection/16 ml | Bevacizumab - Onus Pharma
Bevixa 400 mg/16 mL is a biologic cancer therapy containing bevacizumab, a monoclonal antibody targeting VEGF to inhibit tumor angiogenesis. Administered via intravenous infusion, it’s indicated for conditions like metastatic colorectal, non‑squamous NSCLC, renal, ovarian, cervical cancers, and glioblastoma. Common side effects include hypertension, proteinuria, bleeding, headache, and dry skin.
Bevixa 400 mg (Injection) is a biologic medication. It is known as endothelial vascular growth factor receptor used to treat different types
